MultiGeneAngio from Israel’s VESSL Therapeutics is in human trials for treating peripheral and coronary artery disease. The patient’s cells are extracted, enhanced with genes and re-implanted, to increase blood flow to oxygen-starved muscles. And VESSL’s MultiGeneGraft treats end-stage renal disease.